Recently, some studies reported that MSH2 mutation carriers were more prone to develop extracolonic cancers or multiple tumors, while carriers of MSH6 mutations had a higher frequency of endometrial cancer (18). This evidence concerns the gene MSH2 and endometrial cancer.